menu
    • menu
    [{"orgOrder":0,"company":"Kuros Biosciences","sponsor":"Avania | Kuros Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TGplPTH1-34","moa":"Parathyroid hormone-1 receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Kuros Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kuros Biosciences \/ Avania | Kuros Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Kuros Biosciences \/ Avania | Kuros Biosciences"},{"orgOrder":0,"company":"Kuros Biosciences","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2021","type":"Acquisition","leadProduct":"Vidutolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II","graph3":"Kuros Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Kuros Biosciences \/ XOMA","highestDevelopmentStatusID":"8","companyTruncated":"Kuros Biosciences \/ XOMA"}]

    Find Clinical Drug Pipeline Developments & Deals by Kuros Biosciences

    Menu

    Kuros Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kuros Biosciences

                            Switzerland arrow
                            OPRD
                            Not Confirmed

                            Kuros Biosciences

                            Switzerland arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vidutolimod,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : XOMA

                            Deal Size : $32.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Biosciences

                            Details : Vidutolimod triggers the body’s innate immune system to attack tumors in combination with other therapies. XOMA has acquired all future potential royalties from commercial sales of vidutolimod, which are tiered from high-single to double digits.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            July 15, 2021

                            Lead Product(s) : Vidutolimod,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : XOMA

                            Deal Size : $32.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kuros Biosciences

                            Switzerland arrow
                            OPRD
                            Not Confirmed

                            Kuros Biosciences

                            Switzerland arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TGplPTH1-34

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase II

                            Sponsor : Avania | Kuros Biosciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            KUR-113 Bone Graft Versus Local Autograft for the Treatment of Single-level Transforaminal Lumbar Interbody Fu...

                            Details : TGplPTH1-34 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Intervertebral Disc Degeneration.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 03, 2020

                            Lead Product(s) : TGplPTH1-34

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase II

                            Sponsor : Avania | Kuros Biosciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth